The changes in visual function after intravitreal bevacizmab for ocular neovascular diseases

The changes in visual function after intravitreal bevacizmab for ocular neovascular diseases - The changes in visual function after intravitreal bevacizmab for ocular neovascular diseases

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021074

Enrollment

Registered

2016-02-17

Start date

2012-12-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular neovascular diseases

Interventions

One or more intravitreal bevacizmab. The dose is 1.25mg.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Ocular neovascular diseases

Exclusion criteria

Exclusion criteria: Ocular non-neovascular diseases

Design outcomes

Primary

Measure	Time frame
Visual acuity and Activity of ocular neovascularization for 24 months after injection	—

Countries

Japan

Contacts

Public ContactHiroki Otsuka

Kagoshima university Ophthalmology

otsuka-@m2.kufm.kagoshia-u.ac.jp+81-99-275-5402

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026